Inicio・Lista de Acciones・Corcept Therapeutics Inc

Corcept Therapeutics Inc

Cerrado

SectorSanidad

90.8 -5.13

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

90.44

Máximo

95.61

Métricas clave
By Trading Economics
Ingresos	-130M -32M
Ventas	-37M 165M
P/B Media del Sector	254.361 62.58
BPA	-0.3
Margen de beneficios	-19.26
Empleados	730
EBITDA	-55M -44M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+1.93% upside

Dividendos
By Acuity
Próximas Ganancias	30 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	4.9B 9.8B
Apertura anterior	95.93
Cierre anterior	90.8

Noticias sobre sentimiento de mercado

By Acuity

46%

54%

133 / 340 Clasificación en Healthcare

Corcept Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 17:06 UTC

Corcept Therapeutics Inc is trading higher today, reflecting broader market trends as regional indices like the Nikkei 225 also show gains.

20 jul 2026, 18:13 UTC

Social Media

Corcept Therapeutics shares are higher today, boosted by FDA approval of Lifyorli and increased trading volume amid heightened investor interest.

Comparación entre iguales

Cambio de precio

Corcept Therapeutics Inc previsión

Precio Objetivo

By TipRanks

1.93% repunte

Estimación a 12 Meses

Media 97.5 USD 1.93%

Máximo 135 USD

Mínimo 72 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Corcept Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Corcept Therapeutics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

133 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.